Format

Send to

Choose Destination
Calcif Tissue Int. 2010 Nov;87(5):437-49. doi: 10.1007/s00223-010-9399-3. Epub 2010 Sep 15.

Potential of resveratrol analogues as antagonists of osteoclasts and promoters of osteoblasts.

Author information

1
Division of Hematology, Department of Clinical Cell Biology, Vejle Hospital, IRS/CSFU, University of Southern Denmark, Vejle, Denmark. kkupisiewicz@health.sdu.dk

Abstract

The plant phytoalexin resveratrol was previously demonstrated to inhibit the differentiation and bone resorbing activity of osteoclasts, to promote the formation of osteoblasts from mesenchymal precursors in cultures, and inhibit myeloma cell proliferation, when used at high concentrations. In the current study, we screened five structurally modified resveratrol analogues for their ability to modify the differentiation of osteoclasts and osteoblasts and proliferation of myeloma cells. Compared to resveratrol, analogues showed an up to 5,000-fold increased potency to inhibit osteoclast differentiation. To a lesser extent, resveratrol analogues also promoted osteoblast maturation. However, they did not antagonize the proliferation of myeloma cells. The potency of the best-performing candidate in vitro was tested in vivo in an ovariectomy-induced model of osteoporosis, but an effect on bone loss could not be detected. Based on their powerful antiresorptive activity in vitro, resveratrol analogues might be attractive modulators of bone remodeling. However, further studies are required to establish their efficacy in vivo.

PMID:
20842496
PMCID:
PMC2964465
DOI:
10.1007/s00223-010-9399-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center